The Synergistic Effects of Pyrotinib Combined With Adriamycin on HER2-Positive Breast Cancer

Pyrotinib (PYR) is a pan-HER kinase inhibitor that inhibits signaling via the RAS/RAF/MEK/MAPK and PI3K/AKT pathways. In this study, we aimed to investigate the antitumor efficacy of pyrotinib combined with adriamycin (ADM) and explore its mechanisms on HER2(+) breast cancer. We investigated the eff...

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Foilsithe in:Front Oncol
Main Authors: Wang, Chaokun, Deng, Shuzhen, Chen, Jing, Xu, Xiangyun, Hu, Xiaochen, Kong, Dejiu, Liang, Gaofeng, Yuan, Xiang, Li, Yuanpei, Wang, Xinshuai
Formáid: Artigo
Teanga:Inglês
Foilsithe: Frontiers Media S.A. 2021
Ábhair:
Oncology
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8177085/
https://ncbi.nlm.nih.gov/pubmed/34094901
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.616443
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla